ERBB2 and breast cancer: A high consensus was reached by the SCMs for offering genetic counselling (GC)/genetic testing (GT) to all HER2-negative metastatic BC patients if resources permit and having a delayed progression after the use of PARPi in BRCA carriers with metastatic HER2-negative BC.